Literature DB >> 10928180

Nonlinear discriminant analysis and prognostic factor classification in node-negative primary breast cancer using probabilistic neural networks.

J M Le Goff1, L Lavayssière, J Rouëssé, F Spyratos.   

Abstract

BACKGROUND: We used non-linear kernel discriminant analysis (KDA) to predict the outcome of 134 axillary node-negative primary breast cancer patients not treated with adjuvant therapy in a non censored database. MATERIAL: Posterior probabilities of relapse at 5 years were estimated using probabilistic neural networks (PNN) and a cross-validation (leave-one-out) technique to avoid overfitting the data. A stepwise method was used to construct the models to define the best combination of risk factors among eleven prognostic factors: age, menopausal status, Scarff-Bloom-Richardson grade, clinical tumor size, pathological tumor size, estrogen and progesterone receptor status, urokinase-type plasminogen activator, p53 protein level, c-erbB-2 protein and epidermal growth factor receptor. The different variables were tested individually and in combination to determine their prognostic power using a ROC indicator, which measures the separation between the probability distributions of the output neuron activations under the null hypothesis (no recurrence at 5 years) and under the alternative hypothesis (recurrence at 5 years).
RESULTS: The best predictive one-dimensional model was obtained with uPA (ROC indicator = 0.75). A two-factor model including uPA and clinical tumor size (T) gave the best discrimination between recurrence and non recurrence at 5 years (ROC indicator = 0.84). Additional variables did not improve the accuracy of the prediction. The uPA-T model generated a map useful in predicting the posterior probability of cancer recurrence in a given patient. This representation allows the entire database to be easily visualized and each patient can be compared with the entire database.
CONCLUSION: This is a powerful approach to analyze the impact of prognostic factors and it could find clinical applications in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10928180

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Artificial neural networks for assessing the risk of urinary calcium stone among men.

Authors:  Bertrand Dussol; Jean-Michel Verdier; Jean-Marc Le Goff; Patrice Berthezene; Yvon Berland
Journal:  Urol Res       Date:  2006-01-06

2.  The relative merits of population-based and targeted prevention strategies.

Authors:  Donna M Zulman; Sandeep Vijan; Gilbert S Omenn; Rodney A Hayward
Journal:  Milbank Q       Date:  2008-12       Impact factor: 4.911

3.  A discriminant function model as an alternative method to spirometry for COPD screening in primary care settings in China.

Authors:  Jiangyu Cui; Yumin Zhou; Jia Tian; Xinwang Wang; Jingping Zheng; Nanshan Zhong; Pixin Ran
Journal:  J Thorac Dis       Date:  2012-12       Impact factor: 2.895

4.  Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis.

Authors:  Rodney A Hayward; David M Kent; Sandeep Vijan; Timothy P Hofer
Journal:  BMC Med Res Methodol       Date:  2006-04-13       Impact factor: 4.615

Review 5.  uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.

Authors:  Michael J Duffy; Patricia M McGowan; Nadia Harbeck; Christoph Thomssen; Manfred Schmitt
Journal:  Breast Cancer Res       Date:  2014-08-22       Impact factor: 6.466

6.  The Application of Classification and Regression Trees for the Triage of Women for Referral to Colposcopy and the Estimation of Risk for Cervical Intraepithelial Neoplasia: A Study Based on 1625 Cases with Incomplete Data from Molecular Tests.

Authors:  Abraham Pouliakis; Efrossyni Karakitsou; Charalampos Chrelias; Asimakis Pappas; Ioannis Panayiotides; George Valasoulis; Maria Kyrgiou; Evangelos Paraskevaidis; Petros Karakitsos
Journal:  Biomed Res Int       Date:  2015-08-03       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.